The generic is priced 40% lower than the original drug.
Russia’s Federal Antimonopoly Service (FAS) has approved the price of the country’s first domestically produced generic version of alectinib, an anti-cancer drug, the regulator said in a statement.
The generic medicine, marketed as Alectinib-Amedart (international nonproprietary name: alectinib), will cost 572 roubles per pack for the 150 mg dosage. This is around 40% cheaper than the imported reference drug Alecensa, which costs 954 roubles per capsule at the same dosage.
According to the FAS, the price approval for the new domestic generic is expected to improve affordability and expand patient choice once patent protection for the original drug expires.
Alectinib was added to Russia’s list of essential medicines in 2019.
The original drug Alecensa, produced by Switzerland’s F. Hoffmann-La Roche Ltd, was granted state registration in Russia in March 2021 in capsule form, according to the state drug register. Its marketing authorization is valid until 26 August 2026.
The first Russian generic, Alectinib-Amedart, manufactured by pharmaceutical company Amedart, was registered in November 2025.
Source: Pharmvestnik
